PL398967A1 - Zastosowanie kwasu loganowego w terapii jaskry - Google Patents
Zastosowanie kwasu loganowego w terapii jaskryInfo
- Publication number
- PL398967A1 PL398967A1 PL398967A PL39896712A PL398967A1 PL 398967 A1 PL398967 A1 PL 398967A1 PL 398967 A PL398967 A PL 398967A PL 39896712 A PL39896712 A PL 39896712A PL 398967 A1 PL398967 A1 PL 398967A1
- Authority
- PL
- Poland
- Prior art keywords
- acid
- glaucoma therapy
- loganic acid
- loganic
- glaucoma
- Prior art date
Links
- JNNGEAWILNVFFD-DXNVVGTLSA-N 7-Epiloganic acid Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)C[C@@H](O)[C@@H]2C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JNNGEAWILNVFFD-DXNVVGTLSA-N 0.000 title abstract 2
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- WMQIBEYREGDWOS-UOUCRYGSSA-N Loganic acid Natural products CC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3C[C@H](O)[C@H](C)[C@@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O WMQIBEYREGDWOS-UOUCRYGSSA-N 0.000 title abstract 2
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 title abstract 2
- JNNGEAWILNVFFD-UHFFFAOYSA-N epiloganic acid Natural products CC1C(O)CC(C(=CO2)C(O)=O)C1C2OC1OC(CO)C(O)C(O)C1O JNNGEAWILNVFFD-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Przedmiotem wynalazku jest zastosowanie kwasu sloganowego do wytwarzania leku lub wyrobu medycznego do stosowania w terapii jaskry. Substancja czynna jest kwas loganowy o wzorze 1, którego dzialanie polega na obnizaniu cisnienia wewnatrzgalkowego i zwiekszeniu przeplywów w naczyniach krwionosnych oczu.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL398967A PL222033B1 (pl) | 2012-04-24 | 2012-04-24 | Zastosowanie medyczne kwasu loganowego |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL398967A PL222033B1 (pl) | 2012-04-24 | 2012-04-24 | Zastosowanie medyczne kwasu loganowego |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL398967A1 true PL398967A1 (pl) | 2013-10-28 |
| PL222033B1 PL222033B1 (pl) | 2016-06-30 |
Family
ID=49449315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL398967A PL222033B1 (pl) | 2012-04-24 | 2012-04-24 | Zastosowanie medyczne kwasu loganowego |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL222033B1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115607589B (zh) * | 2020-04-24 | 2024-06-04 | 广州岐微生物医药科技有限公司 | 秦艽及其单体化合物在杀螨中的应用 |
-
2012
- 2012-04-24 PL PL398967A patent/PL222033B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL222033B1 (pl) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| MY175997A (en) | Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| EP4302734A3 (en) | Ocular delivery systems and methods | |
| PH12016500433B1 (en) | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | |
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| SG10201804746WA (en) | Surgical methods employing purified amphiphilic peptide compositions | |
| MX2016009063A (es) | Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. | |
| IN2014KN02617A (pl) | ||
| BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
| MX2014000781A (es) | Dosis combinada fija de bimatoprost y brimonidina. | |
| MX2018001918A (es) | Aplicación cuantitativa periorbital de farmacos oftalmologicos. | |
| BR112017023170A2 (pt) | dispositivo de banho medicinal e seu uso | |
| MX355770B (es) | Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico. | |
| JP2013534527A5 (pl) | ||
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| MX2015014939A (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| IN2014CN04809A (pl) | ||
| UA113966C2 (xx) | Водна рідка фармацевтична композиція, яка містить арбекацин | |
| SG11201408323RA (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
| MX2015008676A (es) | Formulaciones de nanoparticulas de metadichol, liquidas y en gel. | |
| EA201600469A1 (ru) | Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости | |
| UA108975C2 (uk) | Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями | |
| EA201200466A1 (ru) | Терапевтический газ для лечения митохондриальных расстройств | |
| PL398967A1 (pl) | Zastosowanie kwasu loganowego w terapii jaskry |